Cell therapy as routine haematology
CAR-T and other cell therapies are normalising into haematology practice.
Cell therapy is no longer experimental in haematology. The story now is operational - the apheresis-to-infusion turnaround, the bridging-therapy reality, and the centre-of-excellence access pattern that determines who gets treated.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.